Keryx Biopharmaceuticals, Inc. (KERX) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Keryx (KERX) Volatility Could Increase on Zerenex PDUFA Date Delay, but Risk Negligible - Roth
May 8, 2014 11:22 AM EDTRoth Capital maintains its Buy rating and $30 price target on Keryx Biopharmaceuticals Inc. (KERX) following the company's Q1 report, which was issued ahead of the bell Thursday morning.
Keryx reported Q1 EPS of ($0.15), $0.07 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $10 million versus the consensus estimate of $9.91 million. At March 31, 2014, the Company had cash, cash equivalents, short-term investments and interest receivable of $155.1 million, as compared to $55.7 million at December 31,... More
